Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis. PLoS Negl Trop Dis 2017;11(2):e0005372. https://www.ncbi.nlm.nih.gov/pubmed/28212414
Mutapi F, Maizels R, Fenwick A, Woolhouse M. Human schistosomiasis in the post mass drug administration era. Lancet Infect Dis 2017;17(2):e42–e8. https://www.ncbi.nlm.nih.gov/pubmed/27988094
Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JL, Estanislao GG, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016;16(2):199–208. https://www.ncbi.nlm.nih.gov/pubmed/26511959
Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 2014;8(11):e3286. https://www.ncbi.nlm.nih.gov/pubmed/25412105
